Brokerages Anticipate BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Will Post Earnings of $0.33 Per Share

Share on StockTwits

Wall Street analysts expect that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post $0.33 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.45. BioMarin Pharmaceutical posted earnings of $0.14 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 135.7%. The firm is scheduled to report its next earnings results on Thursday, October 24th.

According to Zacks, analysts expect that BioMarin Pharmaceutical will report full-year earnings of $0.81 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.90. For the next fiscal year, analysts forecast that the business will report earnings of $1.67 per share, with EPS estimates ranging from $0.97 to $2.54. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The firm had revenue of $388.00 million for the quarter, compared to analyst estimates of $415.03 million. During the same period in the previous year, the business posted ($0.09) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 4.0% compared to the same quarter last year.

Several analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and set a $131.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, April 26th. BidaskClub lowered BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, July 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $133.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, August 5th. Citigroup reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Thursday, May 23rd. Finally, Robert W. Baird set a $120.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Friday, April 26th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $115.60.

Shares of NASDAQ:BMRN traded up $4.77 during trading on Tuesday, hitting $76.50. 1,825,500 shares of the stock were exchanged, compared to its average volume of 1,207,601. BioMarin Pharmaceutical has a 1-year low of $71.53 and a 1-year high of $106.74. The company has a market capitalization of $12.87 billion, a price-to-earnings ratio of -231.82 and a beta of 1.35. The company’s fifty day simple moving average is $80.43 and its 200-day simple moving average is $86.40. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.79 and a current ratio of 4.11.

In related news, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $81.08, for a total value of $304,050.00. Following the sale, the director now owns 27,340 shares of the company’s stock, valued at approximately $2,216,727.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.90% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of BMRN. Rational Advisors LLC boosted its stake in BioMarin Pharmaceutical by 3,211.1% in the first quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 289 shares in the last quarter. Doyle Wealth Management acquired a new position in BioMarin Pharmaceutical in the second quarter worth $26,000. Berman Capital Advisors LLC boosted its stake in BioMarin Pharmaceutical by 56.8% in the first quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 151 shares in the last quarter. Twin Tree Management LP acquired a new position in BioMarin Pharmaceutical in the first quarter worth $36,000. Finally, Trust Co. of Vermont acquired a new position in BioMarin Pharmaceutical in the first quarter worth $44,000. 96.86% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also: What does a hold rating mean?

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.